Skip to main content
SpringerLink
Log in

Necitumumab value-based range $US563-$1309 per cycle

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Goldstein DA, et al. Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost. JAMA Oncology : 27 Aug 2015. Available from: URL: http://dx.doi.org/10.1001/jamaoncol.2015.3316

    PubMed  Google Scholar 

  2. Djulbegovic B. Value-Based Cancer Care and the Excessive Cost of Drugs. JAMA Oncology : 27 Aug 2015. Available from: URL: http://dx.doi.org/10.1001/jamaoncol.2015.3302

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Necitumumab value-based range $US563-$1309 per cycle. PharmacoEcon Outcomes News 736, 17 (2015). https://doi.org/10.1007/s40274-015-2427-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2427-9

Search

Navigation